Tocilizumab-Bavi 80 mg/4ml Suppliers & Bulk Manufacturers
Available Forms: Intravenous infusion
Available Strengths: 80 mg/4ml
Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).
Category: Biosimilars
Tofidence, a biosimilar to Actemra (tocilizumab), blocks interleukin-6 (IL-6) receptors, reducing inflammation and cytokine activity. It effectively treats rheumatoid arthritis, juvenile idiopathic arthritis, and cytokine storm. Benefits include similar efficacy, lower costs, increased accessibility, and improved management of inflammatory and autoimmune diseases when used under medical supervision.
Product Description:
Ofidence, a biosimilar to Actemra (tocilizumab), is regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality according to GMP standards. In the US, FDA approval involves extensive comparability data, clinical validation, and safety assessments. In the EU, CE marking confirms conformity with MDR standards. These biosimilars undergo validation, stability testing, and audits, with comprehensive documentation including biosimilarity, clinical data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, high-quality biosimilar therapies for inflammatory and autoimmune diseases globally.
Tocilizumab-Bavi — third party manufacturing & bulk supply
Tocilizumab-Bavi 80 mg/4ml is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Tocilizumab-Bavi is supplied as Intravenous infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Tocilizumab-Bavi listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Tocilizumab-Bavi →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Insulin‑Aspart‑Szjj
Strength:
100 units/mL
Form: SQ Injection
Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.
View Details
Eculizumab‑Aeeb
Strength:
300 mg/20 mL (IV infusion),
Form: Injection for intravenous infusion
Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris
View Details
Omalizumab‑Igec
Strength:
75 mg/0.5 mL and 150 mg/mL
Form: Pre filled syringe
Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair
View Details
Denosumab(Others Approved)
Strength:
60 mg, 120 mg
Form: Subcutaneous injection
Reference Brands: Xgeva(US & EU) Ospomyv, Xbryk, Merilog, Stoboclo, Zadenvi, Enwylma, Denbrayce, Izamby - biosimilar to Xgeva
View DetailsQuick Response Guaranteed | Verified Suppliers
